ENZ Enzo Biochem Inc.

Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter 2016 and Full Year Results Friday, October 14, 2016 at 8:30 AM E.T.

Enzo Biochem, Inc. (NYSE:ENZ), will hold a conference call to discuss fiscal 2016 fourth quarter and full year results, Friday, October 14, 2016, at 8:30 AM E.T.

To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024. When prompted, use PIN number 85947927. Dial in approximately ten minutes prior to the scheduled teleconference time. A rebroadcast of the call will be available starting approximately two hours after the conference call ends, through midnight (E.T.) Friday, October 28, 2016. The replay of the conference call can be accessed by dialing 1-800-585-8367 (International callers can dial 1-404-537-3406) and, when prompted, use the same PIN number 85947927.

Enzo’s conference call can also be accessed live over the Internet at: http://tinyurl.com/hlgvp9k

To listen to the live call, individuals should go to the web site at least 15 minutes early to register, download and install any necessary audio software. Any pop up blocker installed on your PC should be disabled while accessing the webcast.

A press release announcing fourth quarter results will be distributed, Thursday, October 13, 2016 after the market closes.

Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses are dependent on a number of factors outside of the control of the company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2015. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.

EN
06/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Enzo Biochem Inc.

 PRESS RELEASE

Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Tran...

Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction Transaction Follows Completion of Comprehensive Strategic Review by Special Committee of the Board to Maximize Shareholder Value Farmingdale, NY, June 24, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (OTCQX: ENZB) (“Enzo” or the “Company”) today announced that on June 23, 2025, following the market close, it entered into an Agreement and Plan of Merger (the “Merger Agreement”) to be acquired by Battery Ventures, a global, technology-focused investment firm, through its newly formed entity Bethpage Parent, Inc. ...

 PRESS RELEASE

Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results

Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results FARMINGDALE, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (OTCQX: ENZB) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2025. Financial Highlights The Company’s third-quarter revenue of $6.4 million declined by $1.6 million or 20% compared to the same period in the prior year across all geographic areas. This is due to general continued headwinds in the life sciences tools space, including decreases in government grants, reduced R&D budgets, and tariffs unce...

 PRESS RELEASE

Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Re...

Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction Forms Special Committee of the Board to Lead Evaluation of Viable Options for Maximizing Shareholder Value Engages Independent Financial and Legal Advisors to Support Thorough Process Remains Committed to Maintaining Focus on Cost Containment, Cash Preservation and Near-Term Initiatives to Enhance Value Farmingdale, NY, April 22, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (OTCQX: ENZB) (“Enzo” or the “Company”) today announced that its Board of Directors ...

 PRESS RELEASE

Enzo Biochem Announces Notification to New York Stock Exchange of Inte...

Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX FARMINGDALE, N.Y., March 28, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced its intention to voluntarily delist its common stock from The New York Stock Exchange (“NYSE”) and to have its common stock quoted on the OTCQX Best Market (“OTCQX”). Enzo provided notice of the voluntary delisting to the NYSE on March 28, 2025 and intends to timely file a notification of removal from listing on ...

 PRESS RELEASE

Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results

Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results FARMINGDALE, N.Y., March 17, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal second quarter ended January 31, 2025, with sequential quarter improvement in revenue, gross margin and operating profit / loss. Financial Highlights The Company’s second-quarter gross margin percentage of 52% increased sequentially from 37% during Q1 2025 and increased from 49% during the second quarter of the prior year. These improvements were driven by change in re...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch